SG11202010094TA - Methods of diagnosing and treating based on site-specific tau phosphorylation - Google Patents

Methods of diagnosing and treating based on site-specific tau phosphorylation

Info

Publication number
SG11202010094TA
SG11202010094TA SG11202010094TA SG11202010094TA SG11202010094TA SG 11202010094T A SG11202010094T A SG 11202010094TA SG 11202010094T A SG11202010094T A SG 11202010094TA SG 11202010094T A SG11202010094T A SG 11202010094TA SG 11202010094T A SG11202010094T A SG 11202010094TA
Authority
SG
Singapore
Prior art keywords
diagnosing
site
methods
tau phosphorylation
specific tau
Prior art date
Application number
SG11202010094TA
Inventor
Nicolas Barthelemy
Randall John Bateman
Eric Mcdade
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of SG11202010094TA publication Critical patent/SG11202010094TA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
SG11202010094TA 2018-05-03 2019-05-03 Methods of diagnosing and treating based on site-specific tau phosphorylation SG11202010094TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862666504P 2018-05-03 2018-05-03
US201862666509P 2018-05-03 2018-05-03
PCT/US2019/030725 WO2019213612A1 (en) 2018-05-03 2019-05-03 Methods of diagnosing and treating based on site-specific tau phosphorylation

Publications (1)

Publication Number Publication Date
SG11202010094TA true SG11202010094TA (en) 2020-11-27

Family

ID=68386729

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202010094TA SG11202010094TA (en) 2018-05-03 2019-05-03 Methods of diagnosing and treating based on site-specific tau phosphorylation

Country Status (11)

Country Link
EP (1) EP3788062A4 (en)
JP (1) JP7301394B2 (en)
KR (1) KR20210004996A (en)
CN (1) CN112166117A (en)
AU (1) AU2019262220A1 (en)
BR (1) BR112020021782A2 (en)
CA (1) CA3097667A1 (en)
MX (1) MX2020011458A (en)
SG (1) SG11202010094TA (en)
WO (1) WO2019213612A1 (en)
ZA (1) ZA202006348B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016054247A1 (en) 2014-09-30 2016-04-07 Washington University Tau kinetic measurements
CN114555631A (en) * 2019-08-13 2022-05-27 华盛顿大学 Methods of detecting MTBR tau isoforms and uses thereof
CN114761807A (en) * 2019-09-10 2022-07-15 华盛顿大学 Blood-based assays for site-specific tau phosphorylation-based diagnosis and treatment
WO2021202777A1 (en) * 2020-04-01 2021-10-07 Genentech, Inc. Uses of tau phosphosites as biomarkers for alzheimer's disease
CA3203308A1 (en) 2020-11-30 2022-06-02 Enigma Biointelligence, Inc. Non-invasive assessment of alzheimer's disease
CN112763636B (en) * 2020-12-07 2022-04-19 佛山汉腾生物科技有限公司 Peptide map analysis method
KR20230163548A (en) * 2021-03-31 2023-11-30 워싱턴 유니버시티 CSF phosphorylated tau and amyloid beta profiles as biomarkers of tauopathies.
WO2023288336A1 (en) * 2021-07-16 2023-01-19 Washington University Methods of detecting pentasaccharides and treatment and monitoring of lysosomal storage disease
WO2023068173A1 (en) * 2021-10-18 2023-04-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 BIOMARKER FOR EVALUATING INTRACEREBRAL AMYLOID-β ACCUMULATION
KR20240002809A (en) * 2022-06-30 2024-01-08 광주과학기술원 Method for Early Diagnosis and Staging of Alzheimer's Disease and Screening Cerebral Amyloid Deposition Using Phosphorylated Peptide Derived from Tau Protein
KR20240002810A (en) * 2022-06-30 2024-01-08 광주과학기술원 Method for Early Diagnosis and Staging of Alzheimer's Disease and Screening Cerebral Amyloid Deposition Using Phosphorylated Peptide Derived from Alzheimer's Disease Related Protein

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101124247B (en) * 2004-07-30 2013-07-31 礼纳特神经系统科学公司 Antibodies directed against amyloid-beta peptide and uses thereof
US20080220449A1 (en) * 2007-02-08 2008-09-11 Oligomerix, Inc. Biomarkers and assays for Alzheimer's disease
US20110177509A1 (en) * 2008-07-23 2011-07-21 The Washington University Risk factors and a therapeutic target for neurodegenerative disorders
FR2963791B1 (en) * 2010-08-11 2012-09-21 Assist Publ Hopitaux De Paris METHOD OF DIAGNOSING NEURODEGENERATIVE DISEASES
KR20210099167A (en) * 2011-09-19 2021-08-11 악손 뉴로사이언스 에스이 Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
CN104080806B (en) * 2011-10-07 2018-01-19 Ac免疫有限公司 Identify Tau phosphorylation specific antibody
EP2787349A1 (en) * 2013-04-03 2014-10-08 Affiris AG Method for detecting proteinopathy-specific antibodies in a biological sample
TWI708058B (en) * 2013-10-24 2020-10-21 美商納諾索米克斯公司 Biomarkers and diagnostic methods for alzheimer's disease and other neurodegenerative disorders
EP3221349B1 (en) * 2014-11-19 2020-11-04 Axon Neuroscience SE Humanized tau antibodies in alzheimer's disease
WO2017053739A1 (en) * 2015-09-25 2017-03-30 Steen Judith Methods and compositions for tauopathy diagnosis and treatment

Also Published As

Publication number Publication date
KR20210004996A (en) 2021-01-13
EP3788062A1 (en) 2021-03-10
CN112166117A (en) 2021-01-01
JP2021523357A (en) 2021-09-02
EP3788062A4 (en) 2022-02-16
JP7301394B2 (en) 2023-07-03
CA3097667A1 (en) 2019-11-07
AU2019262220A1 (en) 2020-11-12
AU2019262220A8 (en) 2020-12-10
BR112020021782A2 (en) 2021-02-23
WO2019213612A1 (en) 2019-11-07
ZA202006348B (en) 2022-01-26
MX2020011458A (en) 2020-12-07

Similar Documents

Publication Publication Date Title
ZA202006348B (en) Methods of diagnosing and treating based on site-specific tau phosphorylation
IL280566A (en) Systems and methods for affecting cardiac contractility and/or relaxation
SG11202005592QA (en) Financing Methods and Apparatuses
SG11202006026XA (en) Identity verification method and apparatus
GB201820468D0 (en) Brain iterfacing apparatus and method
EP3776465C0 (en) System of vehicle inspection and method thereof
EP3762881A4 (en) System and methods of electronic identity verification
GB2578773B (en) Methods of manufacturing security device components
EP3636876C0 (en) Mechanical integrity test system and method of using same
IL275814A (en) Cryptographic systems and methods for modification of pools of truly random numbers
GB201909196D0 (en) Filter device and method for switching on and/or switching of such filter device
GB2570558B (en) Method and system for monitoring the mass of an object
GB2539086B (en) Portable vacuum chamber and an associated automated test system and method for the testing of electronic devices
GB201809325D0 (en) Apparatus and method for shock testing live ordnance
IL291169A (en) Blood-based assay for diagnosing and treating based on site-specific tau phosphorylation
GB201818741D0 (en) Diagnostic system and method
IL281144A (en) Picture partition method and device
IL276058A (en) Automated inspection and part enrollment
EP3793840C0 (en) Security device and method of manufacture thereof
GB201807414D0 (en) Testing device and method
PT3136354T (en) Method for securing and ensuring the auditability of an electronic vote
SG11201909828QA (en) Device and method for the electrical testing of an electrical component
SG11201909826RA (en) Device and method for the electrical testing of an electrical component
EP3735680C0 (en) Method and device for the simulation of the presence of humans
EP3895375C0 (en) Ims node and method performed therein